1. The Defendant (Counterclaim Plaintiff)’s claim for the cancer diagnosis cost on December 16, 2013 after the diagnosis of the upper cancer (C77) on December 9, 2013.

The principal lawsuit and counterclaim shall be judged together.

1. The following facts may be found either in dispute between the parties or in Gap evidence No. 2 by integrating the purport of the entire pleadings:

On March 30, 2011, the Defendant entered into a contract with the Plaintiff for the Han Plus Integrated Insurance 1004 (Securities Number : B).

B. On August 30, 2013, the Defendant was diagnosed as Gap's sampling (C73) at the Chungcheongnam National University Hospital, and was diagnosed as Gap's sampling dysium, and thereafter, on December 9, 2013, the Defendant was diagnosed as Gap's dysium dysium dysium dysium dysium dysium dysium (C77.9).

C. The terms and conditions of the cancer diagnosis cost clause of the above insurance contract include the following:

Article 2. The definitions and diagnosis confirmation of cancer, miscellaneous and sampling cancer. (1) In this contract, cancer means diseases (see attached Table 2) classified as malicious (viral) cancer in the 5th Standard Disease Classification.

However, the classification number C44 (other diseases corresponding to the malicious life of the skin, classification number C73 (viral viral viral viral viral viral virals of Agral viral viral viral) are excluded. 3 In this contract, Agral viral viral viral viral viral viral viral gral viral viral viral viral viral gral gral vir gral vir gral vir gral vir gral vir gral vir gr gr gr gr gr gr gr gr gr gr gr gr gr gr gr gr al) is as follows: